High-risk fludarabine-pretreated B-cell chronic lymphocytic leukemia's high response rate following sequential DHAP and alemtuzumab administration though in absence of molecular remission

Medical Oncology

Volumn 23, Issue 3, 2006, Pages 359-368

  Majolino, Ignazio ^a   Ladetto, Marco ^b   Locasciulli, Anna ^a   Drandi, Daniela ^b   Benedetti, Fabio ^c   Gallamini, Andrea ^d   Chisesi, Teodoro ^e   De Blasio, Angelo ^f   Boccadoro, Mario ^b   Tarella, Corrado ^b  

^a SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^b MOLINETTE HOSPITAL   (Italy)

^c UO Ematologia   (Italy)

^d S CROCE E CARLE HOSPITAL   (Italy)

^e Ospedale Civile   (Italy)

^f SANTA MARIA GORETTI HOSPITAL   (Italy)

Author keywords

Alemtuzumab; CLL; DHAP, autograft; Unmutated IgVH

Indexed keywords

ALEMTUZUMAB; CHLORPHENIRAMINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; FLUDARABINE; FOSCARNET SODIUM; GANCICLOVIR; MELPHALAN; MITOXANTRONE;

ADULT; ADVANCED CANCER; ARTICLE; AUTOGRAFT; B LYMPHOCYTE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER STAGING; CANCER THERAPY; CELL MOTILITY; CHILL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DERMATITIS; DRUG ERUPTION; DRUG FEVER; FEMALE; HEMOLYTIC ANEMIA; HUMAN; HUMAN CELL; HYPOTENSION; IMMUNOTHERAPY; LUNG INFECTION; MALE; NAUSEA; NEUTROPENIA; PERIPHERAL BLOOD STEM CELL; PILOT STUDY; PRIORITY JOURNAL; RIGOR; RISK FACTOR; THROMBOCYTOPENIA; TREATMENT RESPONSE; VIRUS INFECTION;

ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; FEMALE; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; PILOT PROJECTS; RECURRENCE; REMISSION INDUCTION; STEM CELLS; TREATMENT OUTCOME; VIDARABINE;

EID: 33749393174     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1385/MO:23:3:359     Document Type: Article

References (36)

1. Shanafelt TD, Geyer SM, Kay NE. Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLL. Blood 2004; 103: 1202-1210.
2. Oscier D, Fegan C, Hillmen P, et al. Guidelines Working Group of the UK CLL Forum. British Committee for Standards in Haematology. Guidelines on the diagnosis and management of chronic lymphocytic leukemia. Br J Haematol 2004; 125: 294-317.
3. O'Brien S, Kantarjian H, Beran M, et al. Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment. Blood 1993; 82: 1695-1700.
4. Keating MJ, O'Brien S, Kantarjian H, et al. Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent. Blood 1993; 81: 2878-2884.
5. Seymour JF, Robertson LE, O'Brien S, Lerner S, Keating MJ. Survival of young patients with chronic lymphocytic leukemia failing fludarabine therapy: a basis for the use of myeloablative regimens. Leuk Lymphoma 1995; 18: 493-496.
6. Keating MJ, O'Brien S, Kontoyiannis D, et al. Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia. Leuk Lymphoma 2002; 43: 1755-1762.
7. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999; 94: 1848-1854.
8. Stilgenbauer S, Bullinger L, Lichter P, Dohner H. Genetics of chronic lymphocytic leukemia: genomic aberrations and V(H) gene mutation status in pathogenesis and clinical course. Leukemia 2002; 16: 993-1007.
9. Ritgen M, Lange A, Stilgenbauer S, et al. Unmutated immunoglobulin variable heavy-chain gene status remains an adverse prognostic factor after autologous stem cell transplantation for chronic lymphocytic leukemia. Blood 2003; 101: 2049-2053.
10. Montserrat E. Role of auto- and allotransplantation in B-cell chronic lymphocytic leukemia. Hematol Oncol Clin North Am 2004; 18: 915-926.
11. Osterborg A, Dyer MJ, Bunjes D, et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia: European study group of Campath-1H treatment in chronic lymphocytic leukemia. J Clin Oncol 1997; 15: 1567-1574.
12. Rai KR, Freter CE, Mercier RJ, et al. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol 2002; 20: 3891-3897.
13. Lozanski G, Heerema NA, Flinn IW, et al. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 2004; 103: 3278-3281.
14. Velasquez WS, Cabanillas F, Salvador P, et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone Blood 1988; 71: 117-122.
15. Rodriguez-Monge EJ, Cabanillas F. Long-term follow-up of platinum-based lymphoma salvage regimens. The MD Anderson Cancer Center experience. Hematol Oncol Clin North Am 1997; 11: 937-947.
16. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute - sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996; 87: 4990-4997.
17. Montillo M, Cafro AM, Tedeschi A, et al. Safety and efficacy of subcutaneous Campath-1H for treating residual disease in patients with chronic lymphocytic leukemia responding to fludarabine. Haematologica 2002; 87: 695-700.
18. Tarella C, Zallio F, Caracciolo D, et al. High-dose mitoxantrone + melphalan (MITO/L-PAM) as conditioning regimen supported by peripheral blood progenitor cell (PBPC) autograft in 113 lymphoma patients: high tolerability with reversible cardiotoxicity. Leukemia 2001; 15: 256-263.
19. Tarella C, Benedetti G, Caracciolo D, et al. Both early and committed progenitors are more frequent in peripheral blood than in bone marrow during mobilization induced by high-dose chemotherapy + G-CSF. Br J Haemat 1995; 91: 535-543.
20. Ladetto M, Donovan JW, Harig S, et al. Real-time polymerase chain reaction of immunoglobulin rearrangements for quantitative evaluation of minimal residual disease in multiple myeloma. Biol Blood Marrow Transplant 2000; 6: 241-253.
21. Donovan JW, Ladetto M, Zou G, et al. Immunoglobulin heavy-chain consensus probes for real-time PCR quantification of residual disease in acute lymphoblastic leukemia. Blood 2000; 95: 2651-2658.
22. Ladetto M, Compagno M, Ricca I, et al. Telomere length correlates with histopathogenesis according to the germinal center in mature B-cell lymphoproliferative disorders. Blood 2004; 103: 4644-4650.
23. Voena C, Ladetto M, Astolfi M, et al. A novel nested- PCR strategy for the detection of rearranged immunoglobulin heavy-chain genes in B cell tumors. Leukemia 1997; 11: 1793-1798.
24. Byrd CJ. Mananagement of patients with fludarabine-refractory CLL. Hematology 2004-ASH Educational Program Book, pp. 175-183.
25. Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002; 99: 3554-3561.
26. Lundin J, Kimby E, Bjorkholm M, et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 2002; 100: 768-773.
27. Perkins JG, Flynn JM, Howard RS, Byrd JC. Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population. Cancer 2002; 94: 2033-2039.
28. Magni M, Di Nicola M, Devizzi L, et al. Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion. Blood 2000; 96: 864-869.
29. Scimè R, Indovina A, Santoro A, et al. PBSC mobilization, collection and positive selection in patients with chronic lymphocytic leukemia. Bone Marrow Transplant 1998; 22: 1159-1165.
30. Tournilhac O, Cazin B, Lepretre S, et al. Impact of frontline fludarabine and cyclophosphamide combined treatment on peripheral blood stem cell mobilization in B-cell chronic lymphocytic leukemia. Blood 2004; 103: 363-365.
31. Dreger P, Stilgenbauer S, Benner A, et al. The prognostic impact of autologous stem cell transplantation in patients with chronic lymphocytic leukemia: a riskmatched analysis based on the VH gene mutational status. Blood 2004; 103: 2850-2858.
32. Dreger P, Brand R, Hansz J, et al. Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning. Leukemia 2003; 17: 841-848.
33. Ritgen M, Stilgenbauer S, von Neuhoff N, et al. Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene status: implications of minimal residual disease measurement with quantitative PCR. Blood 2004; 104: 2600-2602.
34. Rizouli V, Gribben Jg J. The role of stem cell transplantation in chronic lymphocytic leukemia. Semin Hematol 2004; 41: 246-253.
35. Byrd JC, Murphy T, Howard RS, et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 2001; 19: 2153-2164.
36. Faderl S, Thomas DA, O'Brien S, et al. Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood 2003; 101: 3413-3415.